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Abstract
Aim: To investigate the existence of TMPRSS2:ERG fusion gene in circulating tumor cells (CTC) from prostate
cancer patients and its potential in monitoring tumor metastasis.  Methods: We analyzed the frequency of TMPRSS2:
ERG and TMPRSS2:ETV1 transcripts in 27 prostate cancer biopsies from prostatectomies, and TMPRSS2:ERG
transcripts in CTC isolated from 15 patients with advanced androgen independent disease using reverse transcription
polymerase chain reaction (RT-PCR).  Fluorescence in situ hybridization (FISH) was applied to analyze the genomic
truncation of ERG, which is the result of TMPRSS2:ERG fusion in 10 of the 15 CTC samples.  Results: TMPRSS2:
ERG transcripts were found in 44% of our samples, but we did not detect expression of TMPRSS2:ETV1.  Using
FISH analysis we detected chromosomal rearrangements affecting the ERG gene in 6 of 10 CTC samples, including
1 case with associated TMPRSS2:ERG fusion at the primary site.  However, TMPRSS2:ERG transcripts were not
detected in any of the 15 CTC samples, including the 10 cases analyzed by FISH.  Conclusion: Although further
study is required to address the association between TMPRSS2:ERG fusion and prostate cancer metastasis, detection
of genomic truncation of the ERG gene by FISH analysis could be useful for monitoring the appearance of CTC and
the potential for prostate cancer metastasis. (Asian J Androl 2008 May; 10: –)
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1    Introduction
Prostate cancer is the most common non-cutaneous
malignancy in men living in developed nations [1].  Most
prostate cancers diagnosed at an early stage are latent,
but once having progressed they become life threatening,
and, despite recent advances, late stage prostate cancer
is still incurable [2].  With the general application of prostate
specific antigen (PSA) testing for prostate cancer screen-
ing and diagnosis, there is also a dilemma in the clinical
treatment of early stage cancers, because it is difficult to
predict their progression potential [2].  Current methods
either over-treat the majority of early prostate cancer
patients who will not die from prostate cancer even with-
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out treatment, or miss the opportunity to cure early stage
aggressive disease.  As it is the metastatic and androgen
independent disease that is responsible for cancer deaths,
detecting signs of aggressive cancer in clinically early
stages of the disease would be invaluable [3, 4].  However,
there are currently no reliable prognostic biomarkers to
predict prostate cancer progression and metastastic po-
tential [2, 4].
Fusion genes have been studied a great deal in hema-
tological malignancies and soft tissue sarcomas, where
they frequently define a tumor subtype and are associ-
ated with prognosis.  The recurrent fusion of the
TMPRSS2 and ETS family transcription factor genes was
recently identified in prostate cancer [5, 6].  Fusion genes
are de novo genes generated in cancer cells.  They can
be used as a marker to detect cancer cells in minimum
residual disease [7], and also as targets for cancer cell
specific treatment [5, 8].  If these fusion genes, particu-
larly the high frequency of TMPRSS2:ERG fusion gene,
play a role in tumor progression and, most importantly,
tumor metastasis, they will be invaluable markers for
treatment stratification and targets for novel forms of
therapy.  However, studies on the association between
TMPRSS2:ETS fusion gene and tumor progression have
generated inconsistent results, and few studies have at-
tempted to address the role of the fusion gene in ad-
vanced metastastic prostate cancer [9–17].
Long distance tumor metastasis is caused by tumor
cell migration from the primary site into the blood stream,
culminating in survival and re-establishment at a new site.
It has been known for 150 years that tumor cells are
detectable in the blood of patients with advanced cancer
[18].  Sampling circulating tumor cells (CTC) may be
used to study genetic and gene expression alterations in
a continual, relatively non-invasive fashion, and to moni-
tor treatment.  Using genetic and/or biomarkers to detect
the CTC might also provide informed treatment planning.
With the recent advances in use of specific antibodies
and various sorting techniques following antibody labeling,
the ratio of epithelial to blood cells can be augmented so
that analysis of these cells is more feasible [19–21].
However, many genes associated with prostate carcino-
genesis are also expressed in hematopoietic cells, and
the existence of non-tumor epithelial cells in the peri-
pheral blood complicates CTC analysis [22, 23].  For
prostate cancer, the detection of micrometastases is also
limited by the lack of specific cancer cell markers [22,
24, 25].  As the TMPRSS2:ERG fusion gene occurs at a
high frequency in prostate cancer and is a specific ge-
netic marker of abnormal prostate cells, we have attempted
to detect its existence in CTC to monitor tumor progres-
sion and metastatic potential.
2    Materials and methods
2.1  Materials
Twenty-seven primary prostate cancer biopsies from
radical prostatectomy and fifteen peripheral blood samples
from patients with advanced prostate cancer (with me-
tastasis or PSA > 40 ng/mL) were obtained from local
hospitals with patients’ consent and local research ethi-
cal committee’s approval.  A cancer biopsy and a blood
sample were available from 1 patient (primary biopsy
PC127 and blood sample PCB34).  The clinico-patho-
logical data are summarized in Tables 1 and 2.  All blood
samples were taken from patients who received second
line hormone therapy, except for PCB32, who was on
first line treatment.  Tissue biopsies were kept snap fro-
zen in liquid nitrogen and all samples in the present study
were confirmed with cancer by a consultant histopatholo-
gist (Dan Berney), who reviewed fresh frozen sections
from the collected tissue.
2.2  Cell separation and circulating tumor cells purifica-
tion from blood samples
Peripheral blood samples were collected in EDTA-
coated tubes and processed as follows.  From a small
volume (5 mL) blood collection, lymphocytes and tu-
mor cells were separated from red cells by spinning in
Ficoll gradient buffer and then used directly for RNA
extraction. From a large volume (20 mL) blood collection,
CTC were purified by magnetic cell sorting.  Initially,
the red blood cells and the majority of the white blood
cells were removed from the 20 mL blood sample by
spinning in an Oncoquick tube pre-filled with separation
buffer (Greiner, Kremsmuenster, Austria).  The aspirate
was then washed twice with Oncoquick washing buffer
and resuspended in MACS running buffer (Miltenyi
Biotech, Surrey, UK) for CTC selection.  A negative se-
lection for cells which were labeled with CD45 (a lym-
phocyte marker) was performed using AutoMACS
(Miltenyi Biotech).  This was followed by a positive se-
lection for cells labeled with EpCAM (Epithelial Cell Ad-
hesion Molecule) microbeads.
2.3  Immunostaining
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EpCam (Abcam, Cambridge, UK) antibodies were used
at concentrations recommended by the manufacturers.
CTC were air dried onto slides, fixed, incubated over-
night with primary antibodies and detected using appro-
priate secondary antibodies.  Nuclear counterstaining was
performed using 4,6-diamidino-2-phenylindole
dihydrochloride (DAPI).  Stained preparations were ana-
lyzed on a Zeiss 510 confocal microscope (Carl Zeiss
Ltd., Jena, Germany).
2.4  RNA extraction and reverse transcription polymerase
chain reaction (RT-PCR) analysis
RNA was extracted from snap frozen tissues and
Ficoll separated cells from the small blood volume
samples using the Trizol method following the manufac-
turer’s instructions (Invitrogen, Carlsbad, CA, USA).  The
RNeasy Mini kit (Qiagen, Crawley, UK) was also used
according to the manufacturer’s instructions to extract
RNA from the CTC.
Reverse transcription of RNA was performed using
the Superscript II enzyme (Invitrogen).  Random prim-
ers (6pN) were used for RNA extracted from the cancer
biopsies and the Poly-A primer was used for RNA from
the circulating cells.
The primers (for TMPRSS2:ERG forward primer
CAGGAGGCGGAGGCGGA and reverse primer
GGCGTTGTAGCTGGGGGTGAG and for TMPRSS2:
ETV1 forward primer CAGGAGGCGGAGGCGGA and
reverse primer TTGTGGTGGGAAGGGGATGTTT) de-
scribed by Tomlins et al. [5, 8] were used for PCR am-
plification with an annealing temperature of 65ºC.  For
standard RT-PCR, 35 cycles were used, and 40 cycles
were used for quantitative RT-PCR (Q-RT-PCR).  β-ac-
tin with the forward primer GATGAGATT GGCATGGC-
TTT and reverse primer CACCTTCAC CGTTCCAGTTT
was used as a positive control.  The Opticon DNA En-
gine 2 (MJ Research, Waltham, USA) was used to per-
form the Q-RT-PCR thermal cycling and Opticon moni-
tor software (MJ Research) was used for data analysis.
2.5  Sequence analysis
PCR products were cloned into the pCR 2.1-TOPO
Vector using the TOPO TA Cloning Kit (Invitrogen).
Single bacterial clones were picked and directly lysed in
PCR buffer for insert amplification using the M13F and
M13R primers and then sequenced using the ABI Prism
3700 DNA Analyser (Applied Biosystem).  DNA sequences
were analyzed using the 4 Peaks software (Netherlands
Cancer Institute, Amsterdam, Netherlands).
2.6  Fluorescence in situ hybridization
The BAC clones (RP11-95I21 and RP11-476D17)
on either side of the ERG gene were obtained from The
Sanger Institute (Cambridge, UK) and differentially la-
beled in red and green fluorescent dyes, as previously
described [26].  CTC cells were dropped onto glass slides
and fixed in situ with ethanol.  Before hybridization, they
were pretreated in 70% acetic acid for 10 min to remove
the cytoplasm.  Then slides and probes were denatured
separately and hybridized overnight at 37ºC following stan-
dard fluorescence in situ hybridization (FISH)
methodology.  Hybridized cells were counterstained by
DAPI and images were captured using an Olympus fluo-
rescence microscope (Olympus Optical Co. Ltd., Tokyo,
Japan) mounted with a cooled coupled device camera
controlled by the computer software Mac Probe 4.3
(Applied Imaging, Newcastle, UK).
2.7  Statistics
The Fisher exact test was performed to compare the
frequency of TMPRSS2:ERG fusion gene between the
primary sample and the CTC.
3    Results
We analyzed 27 primary prostate cancer biopsies
from radical prostatectomy using standard RT-PCR for
both the TMPRSS2:ERG and TMPRSS2:ETV1 fusion
genes.  Of the samples, 12 (44%) were TMPRSS2:ERG
fusion positive and in 7 samples more than one form of
fusion transcripts were detected (Table 1).  The most
common fusion form detected in 9 of the 12 positive
cases was between exon 1 of TMPRSS2 and exon 4 of
ERG (T1/E4), as originally reported by Tomlins et al [5,
8].  Other fusion forms, such as T1/E2, T1/E5 and T2/E5,
as previously reported by Clark et al. [14, 27–30], were
also detected.  The TMPRSS2:ETV1 fusion gene was
not detected in any samples.
As the TMPRSS2:ERG fusion gene occurred at a
very high frequency, we further investigated the possi-
bility of detecting its fusion transcripts by blood testing.
We analyzed 4 peripheral blood samples (one of them,
PCB34, taken from a fusion positive case, PC127) using
standard RT-PCR.  We took 5 mL of blood from each
sample, and failed to detect any fusion products.
Because both lack of CTC in the small blood volume
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and a large amount of lymphocyte contamination could
result in the failure to detect the fusion gene, we further
analyzed the separated CTC from 20 mL blood samples
from patients with advanced androgen independent pros-
tate cancer receiving second line hormone therapy.  The
purity of cancer cells was enriched and each sample con-
tained more than 100 nucleated CD45 negative, cytokeratin/
EpCAM positive cells (Figure 1).  However, of the 15
samples analyzed using both standard RT-PCR and Q-
RT-PCR, including 1 case in which the primary cancer
biopsy was fusion positive, no fusion transcripts were
detected in any CTC (Figure 2A, B).  We confirmed the
sensitivity of our RT-PCR protocol in detecting TMPRSS2:
ERG fusion transcripts by mixing different dilutions of
fusion positive VCaP cells with fusion negative LNCaP
cells.  We detected the fusion product in approximately
20 (100 pg RNA) but not 10 (50 pg RNA) VCaP cells
mixed with 200 LNCaP cells (Figure 2C).
Table 1. Clinical data and fusion gene status of the 27 cases of
prostate cancers with biopsy samples.  aBlood sample from the
same cases is available. bSamples with more than one fusion tran-
scripts coexist. ND, no data; Pos, positive; Neg, negative.
Cases        Age (years) PSA (ng/mL) TMPRSS2:ERG
PC9   83 1264.0 Posb
PC10 ND    ND Neg
PC27 ND    ND Neg
PC28 ND    ND Posb
PC29 ND    ND Neg
PC34 ND    ND Neg
PC39 ND    ND Pos
PC47   71     10.9 Neg
PC48   62    ND Neg
PC63 ND    ND Posb
PC68 ND    ND Neg
PC75   57       6.5 Posb
PC95 ND    ND Posb
PC98   66   197.7 Posb
PC105   79     27.4 Neg
PC127a   66     59.10 Pos
PC130   73       0.53 Posb
WX3   62    ND Neg
WX5   60       6.5 Neg
WX9   70     21.3 Neg
WX16   64       9.7 Pos
WX36   74     39.0 Neg
WX43   71       8.8 Pos
WX48   65       6.9 Neg
WX49   53       8.8 Pos
WX50   63     10.7 Neg
PCaU ND    ND Neg
Figure 1. Representative immunofluorescence of EpCAM positive
(green) circulating tumor cells (CTC) with nuclear counterstain
(blue).  Scale bar = 1 μm.
Figure 2. Reverse transcription polymerase chain reaction (RT-
PCR) results of the TMPRSS2:ERG fusion transcript and β-actin
in the isolated circulating tumor cells (CTC) and positive control
samples. (A): A gel image showing the positive RT-PCR results
(the bands at approximately 600 bp) from VCaP and P127 and lack
of PCR products from the 15 CTC samples. (B): The β-actin RT-
PCR product (121 bp band) from the VCaP and 15 CTC samples.
(C): The RT-PCR result of the TMPRSS2:ERG fusion gene from a
range of numbers of VCaP cells mixed with 200 LNCaP cells. In
each experiment, molecular biology-grade water was used for nega-
tive control and a 1-Kb ladder was used for the DNA size marker.
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Table 2. Clinical characteristics of patients from whom circulating tumor cells (CTC) were obtained and ERG status detected by fluores-
cence in situ hybridization (FISH).  aTMPRSS2:ERG fusion positive in the primary sample. ND: no data; Neg, negative Pos, positive; PSA,
prostate specific antigen.
Cases          Age (years) PSA at sampling (ng/mL) PSA slope (ng/mL/day) Metastasis ERG FISH results
PCB20 87   56.3   0.224 – Pos
PCB21 90 159   0.23 + ND
PCB22 53   19.0 ND + ND
PCB23 82 199.6   0.599 + Pos
PCB24 73   51.8   0 + Neg
PCB25 76 471.0   3.73 + Neg
PCB26 77 152.5   0.25 + ND
PCB27 55   43.6   0.026 – Pos
PCB28 63 667 26.6 + Neg
PCB29 87 164.1 ND + Pos
PCB30 71 153.4   3.86 + Pos
PCB31 73   23.2   0.02 + ND
PCB32 77   11.8 –0.11 + ND
PCB33 78   64.0   0 ND Neg
PCB34a 69   63.9   0.156 + Pos
27–33].  We also found the co-existence of multiple forms
of fusion variants of TMPRSS2:ERG, which correlates
with several previous studies [14, 27–30].  Most
importantly, we detected that ERG truncation generally
resulted from the gene fusion at a high frequency (6/10)
in CTC samples prepared from the peripheral blood, sug-
gesting that cancer cells with TMPRSS2:ERG fusion fre-
quently migrate into the blood vessel for long distance
seeding.  Our observation of TMPRSS2:ERG fusion gene
positive CTC is consistent with a previous observation
where fusion genes were passed on from the primary
As RT-PCR is limited to detecting the fusion tran-
script in single cells, we applied FISH to analyze the ge-
nomic truncation of ERG (which is the result of
TMPRSS2:ERG fusion) in individual cells.  Isolated CTC
from 10 of the 15 blood samples were available for this
type of analysis, and we found ERG truncation in 6 of
them, including the sample accompanied by a TMPRSS2:
ERG fusion positive primary tumor (Table 2, Figure 3).
Although the frequency of TMPRSS2:ERG fusion was
higher than that detected in our primary samples, it was
not statistically significant (P = 0.319)
4    Discussion
There are currently no reliable markers for predict-
ing the behavior of prostate cancer diagnosed at an early
stage.  Subsequently, there is a dilemma as to how to
treat localized tumors, which are increasingly being de-
tected by PSA screening of tumors.  The high frequency
of TMPRSS2:ERG fusion in prostate cancer and the de-
tection of the fusion transcript in early stage cancers and
even pre-cancerous lesions [27, 31] has promted inves-
tigations into the potential of using the fusion product to
predict cancer progression [9–12, 14–17].
In the present study, we detected a high frequency
of the TMPRSS2:ERG fusion gene in primary prostate
cancer biopsies from radical prostatectomy using RT-
PCR, which is comparable to previous studies [5, 14,
Figure 3. Representative fluorescence in situ hybridization (FISH)
images of truncated ERG gene in circulating tumor cells (CTC). (A):
A CTC from PCB27 with a pair of colocalized red (5') and green (3')
signals (arrowhead) and one separated red and green signals (arrows).
(B): A CTC from PCB29 with a pair of colocalized red (5') and green
(3') signals (arrowhead) and two separated red and green signals
(arrows).  Images were captured at 100 × objective lens. Some green
fluorescence background was seen in both cells.  Scale bar = 1 μm.
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tumors to lymph node metastatic cells [34].  The fre-
quency of TMPRSS2:ERG fusion was not significantly
higher in the CTC samples when compared to that de-
tected in our primary samples.  However, the number of
CTC samples analyzed in the present is small, and fur-
ther investigation of this fusion gene in a larger series of
CTC samples will be required.
CTC analysis can be used to monitor tumor progres-
sion and response to therapies [35].  However, no mark-
ers can currently be used to separate cancer from nor-
mal prostate cells.  Truncation of ERG or fusion of
TMPRSS2:ERG is a specific marker for cancer cells.
The TMPRSS2:ERG fusion may be used to detect tu-
mor cells circulating in the blood in a large proportion of
cases, although not all cases of CTC may be identified.
This makes the detection of ERG truncation or
TMPRSS2:ERG fusion in CTC a specific tool for moni-
toring tumor metastasis before apparent long distance
metastasis occurs.  In our study, we detected ERG al-
teration positive cells in two cases of prostate cancers
without detected metastatic tumors.  The present study
has mainly established the principle in detecting
TMPRSS2:ERG fusion in CTC using advanced prostate
cancers.  Further investigation is required to evaluate its
application in monitoring early stage disease.
Although the TMPRSS2:ERG fusion was detected
at the genomic level, we did not detect the fusion tran-
script in any of the CTC isolated from patient blood
samples.  RT-PCR is a sensitive method for detecting
fusion gene transcripts in a small amount of cells.  The
protocol we used can detect a sample containing 20
TMPRSS2:ERG fusion positive cells from the VCaP cell
line.  There are more than 100 prostate epithelial cells in
each of the selected populations from blood samples de-
termined by immunostaining using EpCAM.  Although
we still cannot absolutely exclude the limitation of tech-
nical sensitivity as a reason for the failure to detect the
fusion transcripts in the small number of CTC, it is most
likely that the expression of TMPRSS2:ERG is switched
off/down in the CTC.  First, as all the patients are andro-
gen independent, it is most likely that fusion gene ex-
pression in CTC from these patients is switched-off/down
as a result of androgen ablation therapy [36].  In a previ-
ous report, the expression of TMPRSS2:ERG was not
detectable in androgen independent cancers, including
some metastatic samples, although the genomic fusion
existed in some cases [14].  Second, most of the CTC in
the blood stream fail to proliferate in culture and appear
terminally differentiated, which might also affect fusion
gene expression.
In summary, we have detected a high frequency of
TMPRSS2:ERG fusion not just in the primary tumors
but also in CTC.  Although the expression of TMPRSS2:
ERG fusion gene was not detected in CTC, genomic
detection of the fusion gene by FISH in CTC could be
used clinically to monitor the early signs of prostate can-
cer metastasis.
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